International pharmaceutical company Rosetta Genomics said in a March 20 release that it has been granted a patent allowance and moved a step closer to obtaining a patent for its thyroid cancer test.
Notices of allowance are usually granted by the U.S. Patent Office to acknowledge a product is worthy of a patent pending an incomplete application, according to the U.S. Patent and Trademark Office.
In this case, Rosetta’s Reveal Assay for thyroid cancer was granted the allowance, based on its ability to determine a tumor’s malignancy from a biopsy, the release said.
Rosetta President and CEO Kenneth Berlin said in the release the new test will cut unnecessary surgery by quickly distinguishing between dangerous and harmless tumors.
“We believe due to our proprietary classifier algorithm and microRNA signature, we can help prevent up to 75 percent of unnecessary thyroid surgeries,” Berlin said in the release. This “has the potential to save health care payers an average of approximately $6,000 per patient tested with Reveal.”